Abstract
Background Observational studies have reported an association between use of eye protection and reduced risk of SARS-CoV-2 infection and other respiratory viruses, but as for most non-pharmaceutical interventions for infection control, no randomized trials have been conducted. We conducted a randomized trial to evaluate the effectiveness of recommending the use of glasses in public as protection against being infected with SARS-CoV-2 and other respiratory viruses.
Methods and findings This was a pragmatic, randomized, trial in Norway from 2 February to 24 April 2022 where all adult members of the public who did not regularly wear glasses, had no symptoms of COVID-19 and no COVID-19 in the last 6 weeks, were eligible. Participants randomized to the intervention group were asked to wear glasses (e.g. sunglasses) for 2 weeks when close to others in public spaces. The primary outcome was positive COVID-19 test result notified to the Norwegian Surveillance System for Communicable Diseases (MSIS). Secondary outcomes included positive COVID-19 test result based on self-report and episode of respiratory infection based on self-report of symptoms. We randomized 3717 participants. All were identified and followed up in the registries and 87% responded to the end of study-questionnaire. The proportions with a notified positive COVID-19 test in the national registry were 3.7% in the intervention group (68/1852) and 3.5% (65/1865) in the control group (95% CI for risk difference -1.0% to 1.4%; relative risk 1.10, 95% CI 0.75 to 1.50). The proportions with a positive COVID-19 test based on self-report were 9.6% and 11.5% (95% CI for risk difference -3.9% to 0.1%; relative risk 0.83, 95% CI 0.69 to 1.00). The risk of respiratory infections based on self-reported symptoms was lower in the intervention group (31% vs. 34%; 95% CI for risk difference -3.3% to -0.3%; relative risk 0.90, 95% CI 0.82 to 0.99).
Conclusions Our results indicate that asking people to wear glasses may protect the public against respiratory infections, but the findings are not certain, and the study needs replication. Although the evidence is uncertain, and the effect probably modest at best, wearing glasses may be worth considering as one component in the infection control toolbox since it is a simple, low burden, and low-cost intervention, with few negative consequences.
Trial registration ClinicalTrials.gov Identifier: NCT05217797
Funding The costs of running the trial were covered by the Centre for Epidemic Interventions Research (CEIR), Norwegian Institute of Public Health. The authors received no specific funding for this work
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05217797
Clinical Protocols
https://www.medrxiv.org/content/10.1101/2022.02.04.22270120v1
https://zenodo.org/record/6521815#.YuT1PHZByUk
https://zenodo.org/record/6669688#.YuT1UnZByUk
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethics Committee (REK) of South-East Norway gave ethical approval for this work (application number 428685).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.